Cargando…
Rhenium‐186‐mercaptoacetyltriglycine‐labeled Monoclonal Antibody for Radioimmunotherapy: In vitro Assessment, in vivo Kinetics and Dosimetry in Tumor‐bearing Nude Mice
Stability and immunoreactivity of (186)Re‐labeled monoclonal antibody were examined, and its in vivo kinetics was investigated in tumor‐bearing Balb/c nu/nu female mice to assess the feasibility of using it in radioimmunotherapy (RIT). A murine IgG(1), A7, against a 45 kD glycoprotein in human colon...
Autores principales: | Kinuya, Seigo, Yokoyama, Kunihiko, Tega, Harunobu, Hiramatsu, Takashi, Konishi, Shota, Yamamoto, Wakako, Shuke, Noriyuki, Aburano, Tamio, Watanabe, Naoto, Takayama, Terahiko, Michigishi, Takatoshi, Tonami, Norihisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921918/ https://www.ncbi.nlm.nih.gov/pubmed/9765625 http://dx.doi.org/10.1111/j.1349-7006.1998.tb00642.x |
Ejemplares similares
-
Enhanced Efficacy of Radioimmunotherapy Combined with Systemic Chemotherapy and Local Hyperthermia in Xenograft Model
por: Kinuya, Seigo, et al.
Publicado: (2000) -
Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy
por: Uccelli, Licia, et al.
Publicado: (2017) -
LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Guerra-Garcia, Maria, et al.
Publicado: (2021) -
LMD-13. ReSPECT-LM: Maximum tolerated dose, safety, and efficacy of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Brenner, Andrew, et al.
Publicado: (2021) -
LOCL-04 SAFETY AND FEASIBILITY OF RHENIUM-186 NANOLIPOSOME (186RNL) IN LEPTOMENINGEAL METASTASES [LM] PHASE 1/2A DOSE ESCALATION TRIAL
por: Brenner, Andrew, et al.
Publicado: (2022)